Myeloproliferative Neoplasms (MPN)

This new study from the VHA also shows neither cytoreductive therapy nor phlebotomy clearly lowers thrombosis risk.

Ropeginterferon alfa-2b-njft is expected to be available immediately.

Selinexor, an oral XPO1 inhibitor, delivers modest spleen volume reduction in ruxolitinib-refractory MF with minimal myelosuppression in ESSENTIAL trial news.

FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.

This meta-analysis encompassed 18 studies published through December 31, 2025.

The authors suggest their data could reflect phlebotomy’s role as a reactive rather than sustained control measure.

Each visit incorporated instruments that included symptom burden, fatigue, anxiety and depression, nutritional risk, and patient activation.

Patients with a history of nonmelanoma skin cancer had a 548% greater likelihood to develop another skin cancer vs those with no cancer history.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

New research reveals ruxolitinib’s hidden cholesterol risk in patients who have MPN and pelabresib’s durable benefit when added to ruxolitinib in myelofibrosis.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

Phlebotomy is used in polycythemia vera to reduce hematocrit levels below 45%, and is the most common treatment for the myeloproliferative neoplasm.

New research highlights INCA033989's potential in treating mutCALR-driven essential thrombocythemia and myelofibrosis, achieving significant molecular responses.

A new analysis suggests links between ZRSR2 loss and JAK2 V617R disease progression are indirect and complex.

Myeloproliferative neoplasms–unclassifiable (MPN-U), show distinct genetic and clinical patterns that differentiate them from essential thrombocythemia.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

New treatment options are needed for patients with accelerated-phase or blast-phase myeloproliferative neoplasms (MPNs) ineligible for standard care.

Patients with essential thrombocythemia live with a risk of developing serious bleeding complications, a new study explains.

This case highlights the diagnostic complexity and clinical management challenges of dual hematologic malignancies.

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Outcomes in accelerated-phase (AP) or blast-phase (BP) myeloproliferative neoplasm (MPN) differ from AML, and AML-based frameworks may not fully capture prognosis in this population.

Patients with myeloproliferative neoplasms (MPNs) appear to be at a higher risk of heart failure and pulmonary hypertension, though more research into the links is needed.

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.

The QRISK3 assessment is designed for the general population, but it appears to also have utility in patients with essential thrombosis and polycythemia vera.